Placebo
VIDEO: Latest Healio Rheumatology covers biosimilar switching and the nocebo effect
Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the July issue, including the cover story delving into the issue of interchangeable biosimilar switching.
Atogepant reduces mean monthly migraine days compared with placebo
Treatment with atogepant at 30 mg and 60 mg reduced mean monthly migraine days over 12 weeks compared with placebo, while showing good safety and tolerability profiles, according to research published in the Lancet Neurology.
Peresolimab superior to placebo for rheumatoid arthritis treatment
Peresolimab 700 mg is superior to placebo in the treatment of moderate-to-severe rheumatoid arthritis, according to data published in the New England Journal of Medicine.
Blood pressure-lowering meds more effective than placebo at reducing migraine frequency
A systematic literature review determined that various classes of blood pressure-lowering medication reduced frequency of migraine days per month compared with placebo, according to a study published in Cephalalgia.
VIDEO: LAMP study focuses on atropine for myopia control
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Mark A. Bullimore, MCOptom, PhD, FAAO, discussed the use of atropine for myopia control in the LAMP study.
Opioids yielded no difference in pain severity for low back, neck pain vs. placebo
Results published in The Lancet showed opioids yielded no difference in pain severity for adults with low back and neck pain when compared with placebo.
Upadacitinib impactful vs placebo in psoriatic arthritis with axial involvement
Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.
Polypills may be safe, effective for BP lowering vs. monotherapy, usual care or placebo
Compared with monotherapy, usual care or placebo, polypills containing three or four low-dose antihypertensive drugs were associated with greater achievement of target BP and more sustained BP lowering, according to a meta-analysis.
Placebo adjunct to methadone for OUD improves treatment retention, sleep quality
The use of open-label placebo alongside methadone for opioid use disorder was associated with greater 90-day treatment retention rates and better sleep quality compared with the use of methadone alone, a randomized clinical trial found.
Trial results show gout therapy of pegloticase, methotrexate maintained eGFR vs. placebo
AUSTIN, Texas —Results from a poster presentation here showed that patients with uncontrolled gout treated with the combined therapy of pegloticase and methotrexate saw a reduction in gout symptoms as well as a stable eGFR.